Neurorehabilitation News

The FDA has granted clearance to a Colorado-based medical technology company’s transcutaneous electrical nerve stimulation device for those suffering from chronic pain, according to a press release.

Compared with gross total resection, lobectomy as a surgical intervention for individuals with glioblastoma had a more positive impact on progression-free and overall survival outcomes, according to a systematic review and meta-analysis.

Plasma biomarkers shed light on concussion-related neuropathology in adolescents who played contact sports in Canada, supporting their use in pathophysiology, according to new research.

Topline data from an ongoing clinical trial of a higher dose regimen of Spinraza in treatment-naive, symptomatic infants with spinal muscular atrophy showed significantly improved motor function at 6 months.

A combination therapy led to significant dystrophin expression and functional improvement in patients with Duchenne muscular dystrophy amenable to exon 51 skipping, according to new data from a phase 1/2 clinical trial.

Transcranial static magnetic stimulation did not significantly modify ALS disease progression at 6 months compared with sham, but long-term follow up showed an increase in tracheostomy-free survival, data show.

The first patient has been dosed in a phase 3 clinical trial of oral cladribine for the treatment of generalized myasthenia gravis, according to the manufacturer.

Treatment-limiting decisions were made for almost half of patients with severe traumatic brain injuries, with higher rates in those older in age, according to data.

The FDA has granted fast-track designation to an investigational tau positron emission tomography diagnostic that can be used for a range of neurodegenerative conditions, according to the manufacturer.